Related Experiment Video
Updated: May 11, 2025

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil
Evan Offord1, Michelle Nabi1, Michael Mankbadi1
1Division of Cardiovascular Medicine, Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.
Ritonavir-boosted nirmatrelvir (Paxlovid) can cause serious drug interactions. Combining it with verapamil led to complete heart block and shock in a patient with acute kidney injury.
Area of Science:
- Pharmacology
- Cardiology
- Nephrology
Background:
- Ritonavir-boosted nirmatrelvir (Paxlovid) is a key COVID-19 treatment.
- Ritonavir is a potent cytochrome P450 (CYP) 3A4 inhibitor, increasing the risk of drug-drug interactions.
- Verapamil is a calcium channel blocker often used for cardiovascular conditions.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers